Pharmaco-Kinesis Corporation was created in 2006 to begin the formal research and development of Josh Shachar’s innovative implantable drug delivery pump technology that he and his team had been working on since 1999.

The pump was initially envisioned as a way to provide better delivery of therapeutics for patients who needed regular and ongoing drug delivery for the treatment of persistent diseases. Specifically, Josh wanted to find a way to help cancer patients who required long-term chemotherapeutics be able to receive treatments without being tethered to a treatment center and its associated delivery issues.

“One simply has to look at nature’s profound simplicity of design to see how complex engineering problems can be solved..”
– Josh Shachar.

By creating an implantable pump for delivery, a patient could receive regulated dosages of the therapeutic while maintaining their freedom and quality of life. Secondly, traditional chemotherapy required a large dose of what in essence is a very toxic chemical to be administered to the patient at one sitting. This “maximum tolerable dose” had to be well calculated in order to provide effect for cancer without causing severe side effects for the patient. By using his implantable pump, a patient’s could be metronomically controlled and delivered in microdoses, small amounts of the therapeutic, more frequently. Thereby reducing side, effects and creating a more sustained concentration of the drug in the system. Thirdly, most chemotherapies infused the entire body with the therapeutic, again reducing efficacy and causing unwanted side effects. With Josh’s platform, the pump could be implanted directly on a target site such as a tumor, and the therapeutic delivered directly into the tumor itself.

Creating a therapeutic drug delivery system that was implantable, refillable, and could provide metronomically controlled delivery of a drug directly to a disease site, had the potential to revolutionize this form of cancer treatment as well as other drug-based treatment modalities.

Over the ensuing years, Josh’s team was able to take the idea from vision to benchtop prototype, and formalize proof-of-concept. Several patents were filed and the reality of the vision became clearer.

In 2012 the vision took a major step forward when Josh’s work on a separate technology that would elevate the pump from a simple delivery system to a SMART Pump capable of doing advanced real-time biometric analysis.

Since 2009 Josh and another team had been working on a parallel course developing a new biosensor that would take advantage of recent breakthroughs in micro-miniaturization and biological-to-digital signal measurement to create a chip-sized device capable of measuring in real-time, specific biomarkers, and biometric environmental data. This chip could then perform real-time calculations and initiate processes based on the measurements. This innovative “lab-On-A-Chip” (LOC) technology again had the potential to finally provide a real-world solution for medicine’s need to bridge the biological world with the digital domain.

Several iterations of the biosensor were envisioned, prototyped, and created each with advancing levels of success. In 2012, Josh began to see how his new biosensor technology could take their pump technology to a whole new level of effectiveness by incorporating the LOC technology. For the next four years, the team worked to take the Metronomic Breather Pump, the MBP as it was called, from its then level of development to what became the basis for the SINNAIS System that Cognos Therapeutics is now working to bring to market. With the addition of the biosensor technology, the pump was now able to monitor and calibrate its own mechanical status, take real-time samples of the disease site and tumor, measure important patient vitals, such as temperature, humidity, pressures, and correlate that data into digital information that a physician could monitor remotely from anywhere in the world in order to determine treatment efficacy and to adjust the therapeutic dosages accordingly.

Other technologies that began development under Pharmaco-Kinesis included the MOSFET Catheter, the SMART Brain retractor, and the early development of the portable pathogen detection technology that would eventually become the PRIMUS and OPTIKUS systems.

In 2016 it was decided to take the four areas of technology development that had been brought from vision to prototype validation and to split these into four separate companies that could then move the techs to the next stage of commercial development. Sensor-Kinesis was created to further the biosensor platform, Cognos Therapeutics would handle the Implantable Pump technology, Neuro-Kinesis would forward the SMART medical and surgical tool program and Nano-Kinesis would develop the new nano-particle technologies being created to provide tailor-made, targeted drug therapies.